B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

KAT2A

MOLECULAR TARGET

lysine acetyltransferase 2A

UniProt: Q92830NCBI Gene: 264820 compounds

KAT2A (lysine acetyltransferase 2A) is targeted by 20 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting KAT2A

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Aurintricarboxylic Acid1.102
2juglone hydroxylase [Supplementary Concept] catalyzes1.102
3DEAD-box RNA Helicases0.691
4Thioctic Acid0.691
5Arachidonic Acid0.691
6Oleic Acid0.691
7alpha-Linolenic Acid0.691
8candesartan cilexetil [Supplementary Concept]0.691
9Cisplatin0.691
10diallyl trisulfide0.691
11Estramustine0.691
12gamma-Linolenic Acid0.691
13Hexachlorophene0.691
14Iodoacetamide0.691
15Lithocholic Acid0.691
16Oxytetracycline0.691
17rafoxanide0.691
18Ritonavir0.691
19Thioctic Acid0.691
20Trazodone0.691

About KAT2A as a Drug Target

KAT2A (lysine acetyltransferase 2A) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 20 compounds with documented KAT2A interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

KAT2A inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.